Sivesind Torunn E, Maghfour Jalal, Rietcheck Hope, Kamel Kevin, Malik Ali S, Dellavalle Robert P
Department of Dermatology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Department of Dermatology and Skin Care, Henry Ford Health System, Detroit, Michigan, USA.
JID Innov. 2022 Jan 13;2(2):100095. doi: 10.1016/j.xjidi.2022.100095. eCollection 2022 Mar.
In recent years, cannabinoid (CB) products have gained popularity among the public. The anti-inflammatory properties of CBs have piqued the interest of researchers and clinicians because they represent promising avenues for the treatment of autoimmune and inflammatory skin disorders that may be refractory to conventional therapy. The objective of this study was to review the existing literature regarding CBs for dermatologic conditions. A primary literature search was conducted in October 2020, using the PubMed and Embase databases, for all articles published from 1965 to October 2020. Review articles, studies using animal models, and nondermatologic and pharmacologic studies were excluded. From 248 nonduplicated studies, 26 articles were included. There were 13 articles on systemic CBs and 14 reports on topical CBs. Selective CB receptor type 2 agonists were found to be effective in treating diffuse cutaneous systemic sclerosis and dermatomyositis. Dronabinol showed efficacy for trichotillomania. Sublingual cannabidiol and Δ-9-tetrahydrocannabinol were successful in treating the pain associated with epidermolysis bullosa. Available evidence suggests that CBs may be effective for the treatment of various inflammatory skin disorders. Although promising, additional research is necessary to evaluate efficacy and to determine dosing, safety, and long-term treatment guidelines.
近年来，大麻素（CB）产品在公众中越来越受欢迎。大麻素的抗炎特性引起了研究人员和临床医生的兴趣，因为它们为治疗对传统疗法可能无效的自身免疫性和炎症性皮肤病提供了有前景的途径。本研究的目的是回顾关于大麻素用于皮肤病治疗的现有文献。2020年10月，使用PubMed和Embase数据库对1965年至2020年10月发表的所有文章进行了一次主要文献检索。综述文章、使用动物模型的研究以及非皮肤病学和药理学研究被排除在外。从248项非重复研究中，纳入了26篇文章。其中有13篇关于全身性大麻素的文章和14篇关于局部大麻素的报告。发现选择性2型CB受体激动剂在治疗弥漫性皮肤系统性硬化症和皮肌炎方面有效。屈大麻酚对拔毛癖显示出疗效。舌下含服大麻二酚和Δ-9-四氢大麻酚成功治疗了与大疱性表皮松解症相关的疼痛。现有证据表明，大麻素可能对治疗各种炎症性皮肤病有效。尽管前景广阔，但仍需要进一步研究来评估疗效，并确定剂量、安全性和长期治疗指南。
